Scott Alexander argues that Plan A's proposed AI chip regulations are not a dystopian surveillance state, but rather comparable to existing regulations on controlled substances, and that most feared dystopian outcomes already exist in current banking and AI chat monitoring. Longer summary

Scott defends Plan A's AI chip regulation proposals against claims they would create an Orwellian surveillance state. He compares the proposed regulations (requiring factories, customers, and data centers to register and submit to inspections, plus cryptographic kill switches and transparency requirements) to existing regulations on controlled substances like Xanax, arguing they would simply make the AI chip industry more regulated without dystopian effects. He addresses specific concerns: consumer devices wouldn't need licenses (AI chips cost $40,000+ vs consumer hardware), open-weight models would be banned but replaced with open-algorithm requirements to prevent power concentration, and actual surveillance concerns are already worse in the status quo (banks monitor all transactions, OpenAI monitors chats). Scott argues the real costs are moving chip regulation from 50th to 95th percentile stringency, potentially taxing consumer hardware briefly, and banning new open-weight model training - substantial but not dystopian. Shorter summary

Scott Alexander examines the surprisingly broad effects of GLP-1 drugs like Ozempic, exploring their mechanisms and speculating on why they seem to impact so many different conditions. Longer summary

Scott Alexander explores the wide-ranging effects of GLP-1 receptor agonist medications like Ozempic, which are approved for diabetes and obesity but show promise for many other conditions. He delves into the mechanisms behind their effects on diabetes, weight loss, and addiction, speculating on why these drugs seem to have such broad impacts. The post discusses how GLP-1 drugs work in the brain to reduce hunger and dampen reward systems, potentially explaining their effects on addiction. Scott also touches on their anti-inflammatory properties and potential benefits for neurodegenerative diseases, while cautioning that some reported effects may not replicate. Shorter summary

Scott responds to various comments on his article about supplement labeling, addressing concerns about the industry and providing additional context and analysis. Longer summary

This post is a highlights reel of comments on Scott's previous article about supplement labeling. It covers various points raised by commenters, including skepticism about the supplement industry, concerns about heavy metal contamination, and a defense from the founder of LabDoor. Scott responds to each comment, providing additional context, analysis, and sometimes his own perspective on the issues raised. The post touches on topics such as the efficacy of supplements, the trustworthiness of supplement testing companies, and the potential risks associated with certain types of supplements. Shorter summary

Scott Alexander proposes using high-dose oral progesterone as a potential low-cost alternative to Zulresso for treating postpartum depression, based on pharmacological research. Longer summary

Scott Alexander explores the possibility of using high-dose progesterone as a cheaper alternative to Zulresso for treating postpartum depression. He explains that Zulresso is a metabolite of progesterone and presents research suggesting that a specific regimen of oral progesterone could potentially mimic the effects of Zulresso. The post discusses the pharmacokinetics, dosing schedule, and potential cost savings, with progesterone treatment costing only about $11 compared to Zulresso's $35,000. Scott acknowledges potential obstacles in implementation but hopes researchers will investigate this approach further. Shorter summary

Scott Alexander argues that doctors should prescribe fluvoxamine for COVID-19 despite FDA inaction, urging them to overcome discomfort with off-label use when evidence supports it. Longer summary

Scott Alexander discusses the use of fluvoxamine (Luvox) as a potential treatment for COVID-19. He argues that despite strong evidence from clinical trials showing its effectiveness, many doctors are hesitant to prescribe it due to it being off-label use. The FDA has not added COVID-19 to the drug's label, citing bureaucratic issues. Scott criticizes this inaction and suggests that doctors should be willing to prescribe off-label when evidence supports it, even if it feels uncomfortable. He relates personal experiences of hesitating to prescribe off-label medications due to social pressure and encourages doctors to critically examine their reasons for not prescribing fluvoxamine for COVID-19. Shorter summary

Scott Alexander offers various strategies for obtaining affordable mental health care and medication in the US, including discount programs, therapy alternatives, and supplement options. Longer summary

This post provides detailed advice on how to access mental health care and medication on a budget in the US. Scott outlines various strategies for obtaining prescription medications at lower costs, including using discount websites, pill splitting, and patient assistance programs. He also discusses affordable therapy options and supplement alternatives to prescription drugs. The post is aimed at those who don't qualify for government assistance and includes both legal and potentially legal methods. Scott emphasizes that this is not medical advice and should be used at one's own risk. Shorter summary

The post examines three major issues with generic medications: barriers to market entry, problematic FDA initiatives, and inconsistent pricing across pharmacies. Longer summary

This post discusses the problems with generic medications in the United States, focusing on three main issues. First, it explores why competitors don't easily emerge to challenge price gouging, using the example of Daraprim's price increase. The author suggests that FDA approval processes, including bioequivalence studies, create significant barriers to entry. Second, it critiques the FDA's Unapproved Drugs Initiative of 2006, which allowed companies to gain exclusive rights to public domain drugs by conducting studies, leading to price increases. Finally, it highlights the wide price disparities for generic drugs at different pharmacies, suggesting that comparison shopping can lead to significant savings. Shorter summary